Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Dulaglutide

(Trulicity®)

Dulaglutide

Drug updated on 4/17/2024

Dosage FormInjection (subcutaneous: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL)
Drug ClassGlucagon-like peptide 1 (GLP-1) receptor agonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
  • Indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Dulaglutide (Trulicity) is indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus, as well as for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
  • The information provided was derived from a total of 25 systematic reviews/meta-analyses on dulaglutide (Trulicity).
  • In terms of safety and efficacy, Trulicity has been shown to benefit blood glucose control, weight reduction, and potentially improve cardiovascular outcomes without increasing hypoglycemia risks among T2DM patients with advanced chronic kidney disease (CKD) and end-stage kidney disease (ESKD), compared to other GLP-1 receptor agonists.
  • Compared to other GLP-1 receptor agonists (RAs), dulaglutide is associated with a reduced risk of adverse cerebrovascular outcomes, such as ischemic events, indicating a robust cardiovascular safety profile, especially beneficial for T2DM patients at high stroke risk.
  • When used alongside metformin therapy, dulaglutide effectively lowers HbA1c levels along with body weight. However, newer agents like tirzepatide may offer even greater efficacy than this combination treatment approach.
  • Dulaglutide also exhibits potential neuroprotective effects that could be beneficial beyond glycemic control, although further research is needed to conclusively substantiate these claims.
  • The drug's side effect profile shows lower rates of gastrointestinal issues compared to some GLP-RAs while maintaining low hypoglycemia risks, making it suitable for long-term management strategies.
  • Its once-weekly dosing regimen enhances adherence due to convenience, coupled with a better-tolerated gastrointestinal side effect profile when compared to daily therapies within the same class of drugs.

Product Monograph / Prescribing Information

Document TitleYearSource
Trulicity (dulaglutide) prescribing information.2022Eli Lilly and Company, Indianapolis, IN

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: A systematic review and meta-analysis.2024Diseases
GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: A systematic review and meta-Analysis of randomized controlled trials.2023The Journal of Clinical Endocrinology & Metabolism
Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: A systematic review.2023Frontiers in Endocrinology
Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review.2023Journal of Psychiatric Research
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: A systematic review and network meta-analysis.2023EClinicalMedicine
GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.2023The Journal of Clinical Endocrinology and Metabolism
Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials.2022BMC Endocrine Disorders
Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: A systematic review and meta-analysis of randomized controlled trials.2022Diabetology & Metabolic Syndrome
Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: A systematic review and meta-analysis.2022Scientific reports
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.2022Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: A systematic review and meta-analysis. 2022Scientific Reports
The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.2022Contemporary Clinical Trials Communications
Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.2021Diabetes Research and Clinical Practice
Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.2021International Journal of Clinical Practice
Efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus: A network meta-analysis.2021Advances in Therapy
Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: Systematic review and network meta-analysis.2021Diabetes Therapy
Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.2021Journal of Clinical Pharmacy and Therapeutics
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: A systematic review and meta-analysis of 21 randomized controlled trials.2020Endocrine
Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: Network meta-analysis.2020Cardiovascular Diabetology
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systematic review and network meta-analysis.2020Annals of Internal Medicine
Gastrointestinal adverse events with insulin glargine/ lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.2020Diabetes, Obesity & Metabolism
Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.2020Primary Care Diabetes
Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: A model-based meta-analysis.2019British Journal of Clinical Pharmacology
Efficacy and safety of dulaglutide compared to liraglutide: A systematic review and meta-analysis in patients with type 2 diabetes mellitus.2019Iranian Journal of Pharmaceutical Research
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.2019The Lancet. Diabetes & Endocrinology

Clinical Practice Guidelines

Document TitleYearSource
GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice.2022Journal of the American Association of Nurse Practitioners
KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease.2020Kidney International
Dulaglutide and insulin: How can the AWARD Studies help guide clinical practice?2020Diabetes Therapy